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3,4-methylenedioxyamphetamine (MDA) and 3,4-methylenedioxymethamphetamine
(MDMA) are central nervous system stimulant/hallucinogens and schedule I
controlled substances at the federal level [1]. The analysis of these drugs in crime
labs represents about 0.5% of all drug exhibits in the US [2]. Confirmatory and
quantitative analysis is typically performed by gas chromatographic (GC) analysis.
The highly polar nature of the drugs in both the salt and free base forms cause
strong interactions with surfaces such as the inlet and stationary phase in the GC;
these interactions are problematic, especially for quantitation. Our laboratory
recently developed a method to attenuate this surface interaction that resulted in
improved chromatographic behavior and detector response by mass spectrometry
(MS). We have established that derivatization of the basic nitrogen with alkanoic
anhydrides enhances the sensitivity of the assay significantly.
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Figure 1: MS Full Scan Response for AreaMDA/AreaIS vs [MDA]
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Objectives
The purpose of this project was to apply a quantitative method recently
developed in our lab for several non-controlled substances to two controlled
substances. MDA and MDMA free base were derivatized with several alkanoic
anhydrides and analyzed by GC-MS in full scan mode using a C24 internal
standard.
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Experimental
Sample Preparation: MDA and MDMA salts were purchased from Restek as
DEA exempt solutions in methanol (1.0 mg/mL). 1.0 mL aliquots were
evaporated to dryness. The residues were taken up in 1.0 mL of CHCl3 and
washed with 1N NaOH to produce the free bases (dissolved in CHCl3). Two
additional CHCl3 extractions of the NaOH solution were performed. The
combined extracts were dried through a cotton-plugged Pasteur pipet into a
10.0 mL volumetric flask and diluted to the mark with CHCl3. The amides
were formed on-column with the addition of alkanoic anhydrides and
triethylamine.
Analytical Conditions: Agilent GC-MS Model 7890A/5975C, fitted with a ZB-5
column, 30 m x 0.25 mm i.d. x 0.25 mcm film (MDA) or a HP-1 column, 30 m
x 0.32 mm i.d. x 0.25 mcm film (MDMA), 1.0 mcL injection volume, split ratio
= 5:1, septum purge = 3.0 mL/min, He carrier gas, constant flow = 1.0
o
o
o
mL/min., oven program: 60 C (2.0 min. hold), 30 C/min to 320 C (6 min.
o
o
hold), total run time = 13.667 min., inlet 275 C, MS transfer line 280 C, MS
o
o
source 230 C, MS quad 150 C.
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Figure 2: MS Full Scan Response for AreaMDMA/AreaIS vs [MDMA]

Conclusions
• Derivatization with alkanoic anhydrides enhanced the full scan MS response
significantly compared to the free bases (Fig. 1,2). Also, sensitivity increased with
increasing size of the derivatizing group (base < acetyl < propanoyl < butanoyl).
• Calibration curves were linear in the range of 0.0880 to 0.00400 mg/mL.
• We are grateful to Loyola University Chicago for support of this research project.
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